Venkat P, Yan T, Chopp M, Zacharek A, Ning R, Van Slyke P, Dumont D, Landschoot-Ward J, Liang L, Chen J. Cell Transplant. 2018 Aug 20:963689718791568. doi: 10.1177/0963689718791568. [Epub ahead…
Thamm K, Njau F, Van Slyke P, Dumont DJ, Park JK, Haller H, David S. World J Transplant. 2016 Sep 24;6(3):573-82. doi: 10.5500/wjt.v6.i3.573. PMID: 27683636
Leligdowicz A, Richard-Greenblatt M, Wright J, Crowley VM, KainKC. Front Immunol. 2018Apr 24;9:838. doi: 10.3389/fimmu.2018.00838. eCollection 2018. Review. PMID: 29740443
Parikh SM. Curr Opin Hematol. 2017Sep;24(5):432-438. doi: 10.1097/MOH.0000000000000361. Review. PMID: 28582314
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.